Clinical Trial Update: Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) [Phase 2]

View source ↗

Summary

Phase 2 trial of Saroglitazar Magnesium 4 mg for non-alcoholic fatty liver disease in women with polycystic ovary syndrome (PCOS) was terminated; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Saroglitazar Magnesium (saroglitazar magnesium)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Non-alcoholic Fatty Liver Disease in Women With PCOS | Phase 2 | Status: TERMINATED | Results posted: 2025-12-18